Regulation of microRNA function in animals, Nat. Rev. Mol. Cell Biol, vol.20, pp.21-37, 2019. ,
Widespread changes in protein synthesis induced by microRNAs, Nature, vol.455, pp.58-63, 2008. ,
Most mammalian mRNAs are conserved targets of microRNAs, Genome Res, vol.19, pp.92-105, 2009. ,
Secreted microRNAs: A new form of intercellular communication, Trends Cell Biol, vol.22, pp.125-132, 2012. ,
The Tumor Cytosol miRNAs, Fluid miRNAs, and Exosome miRNAs in Lung Cancer, Front. Oncol, vol.4, 2014. ,
Quantitation of microRNAs by real-time RT-qPCR, Methods Mol. Biol, vol.687, pp.113-134, 2011. ,
The promise of epigenetic therapy: Reprogramming the cancer epigenome, Curr. Opin. Genet. Dev, vol.42, pp.68-77, 2017. ,
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes, Cold Spring Harb. Perspect. Biol, vol.6, 2014. ,
Duration of nuclear NF-kappaB action regulated by reversible acetylation, Science, vol.293, pp.1653-1657, 2001. ,
Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor, J. Biol. Chem, vol.277, pp.25904-25913, 2002. ,
Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain, Cell, vol.90, pp.595-606, 1997. ,
Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation, Cell, vol.111, pp.709-720, 2002. ,
Regulation of E2F1 activity by acetylation, EMBO J, vol.19, pp.662-671, 2000. ,
The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60, Mol. Cell. Biol, vol.24, pp.10826-10834, 2004. ,
Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity, J. Biol. Chem, vol.276, pp.18375-18383, 2001. ,
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor, Mol. Cell, vol.18, pp.601-607, 2005. ,
Stat3 dimerization regulated by reversible acetylation of a single lysine residue, Science, vol.307, pp.269-273, 2005. ,
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo, EMBO J, vol.22, pp.1168-1179, 2003. ,
Interpreting clinical assays for histone deacetylase inhibitors, Cancer Manag. Res, vol.3, pp.117-141, 2011. ,
Discovery and development of SAHA as an anticancer agent, Oncogene, vol.26, pp.1351-1356, 2007. ,
Belinostat: First global approval, Drugs, vol.74, pp.1543-1554, 2014. ,
Panobinostat: A novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma, Expert Rev. Anticancer Ther, vol.15, pp.737-748, 2015. ,
Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: Toxicological point of view, Curr. Med. Chem, vol.11, pp.1629-1643, 2004. ,
Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors, Expert Rev. Anticancer Ther, vol.10, pp.997-1008, 2010. ,
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma, Oncologist, vol.20, pp.1084-1091, 2015. ,
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma, Oncologist, vol.12, pp.1247-1252, 2007. ,
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial, Lancet Oncol, vol.16, pp.447-456, 2015. ,
FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor, Exp. Cell Res, vol.241, pp.126-133, 1998. ,
Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells, Biosci. Biotechnol. Biochem, vol.58, pp.1579-1583, 1994. ,
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma, J. Clin. Oncol, vol.27, pp.5410-5417, 2009. ,
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy, J. Clin. Oncol, vol.30, pp.631-636, 2012. ,
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study, J. Clin. Oncol, vol.33, pp.2492-2499, 2015. ,
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma, Br. J. Haematol, vol.168, pp.811-819, 2015. ,
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma, J. Thorac. Oncol, vol.4, pp.97-101, 2009. ,
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial, Lancet Oncol, vol.15, pp.1195-1206, 2014. ,
Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy, Nutrients, vol.10, p.731, 2018. ,
Histone Deacetylase Inhibitors as Anticancer Drugs, Int. J. Mol. Sci, vol.18, 1414. ,
Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents, Molecules, vol.20, pp.3898-3941, 2015. ,
A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells, Proc. Natl. Acad. Sci, vol.95, pp.6791-6796, 1998. ,
URL : https://hal.archives-ouvertes.fr/hal-01863307
Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression, Cell, vol.75, pp.817-825, 1993. ,
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors, Proc. Natl. Acad. Sci, vol.96, pp.4592-4597, 1999. ,
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1, Proc. Natl. Acad. Sci, vol.101, pp.1241-1246, 2004. ,
but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor, Cancer Res, vol.59, pp.4266-4270, 1999. ,
Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells, Br. J. Pharmacol, vol.153, pp.657-668, 2008. ,
,
, Mol. Cell. Biol, vol.26, pp.2782-2790, 2006.
Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins, Mol. Cancer Ther, vol.1, pp.1181-1190, 2002. ,
Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells, Thyroid, vol.11, pp.315-325, 2001. ,
Deacetylase inhibition in malignant melanomas: Impact on cell cycle regulation and survival, Melanoma Res, vol.14, pp.173-181, 2004. ,
Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma, Neoplasia, vol.7, pp.646-657, 2005. ,
Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells, Cancer Res, vol.64, pp.2580-2589, 2004. ,
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma, Oncogene, vol.24, pp.4609-4623, 2005. ,
Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: Involvement of both death receptor and mitochondrial pathways, Int. J. Mol. Med, vol.16, pp.1125-1138, 2005. ,
Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis, Anticancer Res, vol.28, pp.855-864, 2008. ,
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis, Mol. Cancer Ther, vol.8, pp.3088-3097, 2009. ,
Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity, Adv. Cancer Res, vol.116, pp.165-197, 2012. ,
Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity, Biochem. Biophys. Res. Commun, vol.300, pp.241-246, 2003. ,
Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells, Brain Tumor Pathol, vol.19, pp.77-81, 2002. ,
Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors, Biochem. Pharmacol, vol.66, pp.897-906, 2003. ,
Modulation of angiogenesis-related protein synthesis by valproic acid, Biochem. Biophys. Res. Commun, vol.316, pp.693-697, 2004. ,
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma, European J. Haematol, vol.76, pp.42-50, 2006. ,
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes, Nat. Med, vol.7, pp.437-443, 2001. ,
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha, Cancer Res, vol.66, pp.8814-8821, 2006. ,
Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA, Oncol. Rep, vol.30, pp.961-967, 2013. ,
Epigenetic regulation of tumor endothelial cell anergy: Silencing of intercellular adhesion molecule-1 by histone modifications, Cancer Res, vol.66, pp.10770-10777, 2006. ,
Identification of epigenetically silenced genes in tumor endothelial cells, Cancer Res, vol.67, pp.4138-4148, 2007. ,
Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis, Int. J. Cancer, vol.97, pp.290-296, 2002. ,
MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo, Mol. Cancer Ther, vol.9, pp.3254-3266, 2010. ,
Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275, Cancer Res, vol.64, pp.316-321, 2004. ,
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid, Int. J. Cancer, vol.114, pp.380-386, 2005. ,
Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity, Clin. Cancer Res, vol.11, pp.4912-4922, 2005. ,
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci, Mol. Cancer Ther, vol.5, 1967. ,
Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid, Mol. Cell. Endocrinol, vol.478, pp.141-150, 2018. ,
Attenuated DNA damage repair by trichostatin A through BRCA1 suppression, Radiat. Res, vol.168, pp.115-124, 2007. ,
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination, Proc. Natl. Acad. Sci, vol.104, pp.19482-19487, 2007. ,
Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor, PLoS ONE, vol.5, 2010. ,
Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination, DNA Repair, vol.10, pp.970-977, 2011. ,
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1, Cancer Res, vol.63, pp.3637-3645, 2003. ,
Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells, Int. J. Cancer, vol.99, pp.292-298, 2002. ,
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin, Proc. Natl. Acad. Sci, vol.99, pp.11700-11705, 2002. ,
Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells, Mol. Cells, vol.30, pp.107-112, 2010. ,
In vivo redox state of human thioredoxin and redox shift by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Free Radic, Biol. Med, vol.53, 2002. ,
Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci, vol.99, pp.15524-15529, 2002. ,
Oncomirs-micrornas with a role in cancer, Nat. Rev. Cancer, vol.6, pp.259-269, 2006. ,
The let-7 family of microRNAs, Trends Cell Biol, vol.18, pp.505-516, 2008. ,
Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma, Oncogene, vol.35, pp.3376-3386, 2016. ,
Let-7c Inhibits the Proliferation, Invasion, and Migration of Glioma Cells via Targeting E2F5, Oncol. Res, vol.26, pp.1103-1111, 2018. ,
MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3, Cancer Lett, vol.342, pp.43-51, 2014. ,
Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis, Urol. Oncol. Semin. Orig. Investig, vol.29, pp.265-269, 2011. ,
Circulating miR-18a: A Sensitive Cancer Screening Biomarker in Human Cancer, vol.28, pp.293-297, 2014. ,
Effect of exosomal miRNA on cancer biology and clinical applications, Mol Cancer, vol.17, p.147, 2018. ,
miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy, J. Exp. Clin. Cancer Res, vol.38, 2019. ,
RAS Is Regulated by the let-7 MicroRNA Family, Cell, vol.120, pp.635-647, 2005. ,
Let-7c inhibits cholangiocarcinoma growth but promotes tumor cell invasion and growth at extrahepatic sites, Cell Death Dis, vol.9, p.249, 2018. ,
Let-7c Governs the Acquisition of Chemo-or Radioresistance and Epithelial-to-Mesenchymal Transition Phenotypes in Docetaxel-Resistant Lung Adenocarcinoma, Mol. Cancer Res, vol.11, pp.699-713, 2013. ,
Effects of let-7c on the proliferation of ovarian carcinoma cells by targeted regulation of CDC25a gene expression, Oncol. Lett, vol.16, pp.5543-5550, 2018. ,
MicroRNA let-7c Inhibits Cell Proliferation and Induces Cell Cycle Arrest by Targeting CDC25A in Human Hepatocellular Carcinoma, PLoS ONE, vol.10, 2015. ,
Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer, J. Pathol, vol.226, pp.544-555, 2012. ,
Antiproliferative effect of upregulation of hsa-let-7c-5p in human acute erythroleukemia cells, Cytotechnology, vol.70, pp.1509-1518, 2018. ,
Let-7c-5p inhibits cell proliferation and induces cell apoptosis by targeting ERCC6 in breast cancer, Oncol. Rep, vol.38, pp.1851-1856, 2017. ,
Sequence Variations of MicroRNAs in Human Cancer: Alterations in Predicted Secondary Structure Do Not Affect Processing, Cancer Res, vol.66, pp.6097-6104, 2006. ,
Rapid alteration of microRNA levels by histone deacetylase inhibition, Cancer Res, vol.66, pp.1277-1281, 2006. ,
MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells, Int. J. Oncol, vol.35, pp.1343-1352, 2009. ,
Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines, Exp. Cell Res, vol.318, pp.1832-1843, 2012. ,
A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells, Cancer Biol. Ther, vol.13, pp.681-693, 2012. ,
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: A multicentre, single-arm phase I/II clinical trial, Br. J. Cancer, vol.116, pp.874-883, 2017. ,
Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells, Int. J. Mol. Med, vol.24, pp.45-50, 2009. ,
Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of histone deacetylase inhibitors on ras-transformed thyroid cells, J. Clin. Endocrinol. Metab, vol.98, 2013. ,
The microRNA-200 family: Small molecules with novel roles in cancer development, progression and therapy, Oncotarget, vol.6, pp.6472-6498, 2015. ,
miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells, J. Biol. Chem, vol.286, pp.40725-40733, 2011. ,
HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL, Biochem. Pharmacol, vol.147, pp.30-37, 2018. ,
MicroRNA-31 Is a Transcriptional Target of Histone Deacetylase Inhibitors and a Regulator of Cellular Senescence, J. Biol. Chem, vol.290, pp.10555-10567, 2015. ,
Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells, PLoS ONE, vol.6, 2011. ,
Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia, Blood, vol.119, pp.1162-1172, 2012. ,
Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells ,
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels, Cancer Res, vol.71, pp.3912-3920, 2011. ,
HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b, PLoS ONE, vol.8, 2013. ,
The Role of Myc and the miR-17~92 Cluster in Histone Deacetylase Inhibitor Induced Apoptosis of Solid Tumors, J. Cancer Ther, vol.4, pp.907-918, 2013. ,
Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma, Br. J. Cancer, vol.112, pp.112-121, 2015. ,
Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster, Mol. Carcinog, vol.52, pp.459-474, 2013. ,
Epigenetic regulation of microRNA expression in renal cell carcinoma, Biochem. Biophys. Res. Commun, vol.436, pp.79-84, 2013. ,
HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1, Exp. Cell Res, vol.370, pp.519-530, 2018. ,
HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia, Clin. Cancer Res, vol.22, pp.3537-3549, 2016. ,
Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes, Cancer Lett, vol.353, pp.232-241, 2014. ,
Combination Therapy with Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi, Front. Oncol, vol.8, p.92, 2018. ,
Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer, Mol. Cell. Biochem, vol.383, pp.137-148, 2013. ,
Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies, Cancer Res, vol.76, pp.736-748, 2016. ,
The Microbe-Derived Short Chain Fatty Acid Butyrate Targets miRNA-Dependent p21 Gene Expression in Human Colon Cancer, PLoS ONE, vol.6, 2011. ,
Histone Deacetylase Inhibition Overcomes Drug Resistance through a miRNA-Dependent Mechanism, Mol. Cancer Ther, vol.12, pp.2088-2099, 2013. ,
Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways, PLoS ONE, vol.12, 2017. ,
Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6, Cell Death Discov, 2016. ,
Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor, Cancer Res, vol.76, pp.4192-4204, 2016. ,
The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells, Oncol. Rep, vol.27, pp.10-16, 2011. ,
, HDAC Inhibitors Target HDAC5, Upregulate MicroRNA-125a-5p, and Induce Apoptosis, vol.23, pp.656-666, 2015.
CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway, Sci. Rep, 2017. ,
Epigenetic regulation of microRNA expression in colorectal cancer, Int. J. Cancer, vol.125, pp.2737-2743, 2009. ,
A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts, Nucl. Acids Res, vol.40, pp.6821-6833, 2012. ,
MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta, Cancer Res, vol.70, pp.2339-2349, 2010. ,
Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells, Gastroenterology, vol.143, pp.811-820, 2012. ,
microRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells, Cytotechnology, vol.70, pp.513-521, 2018. ,
Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks, Biochem. Pharmacol, vol.92, pp.299-311, 2014. ,
Epigenetic regulation of microRNA-375 and its role in melanoma development in humans, FEBS Lett, vol.585, pp.2467-2476, 2011. ,
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide, Oncotarget, vol.6, pp.31134-31150, 2015. ,
Anti-Cancer Drugs Reactivate Tumor Suppressor miR-375 Expression in Tongue Cancer Cells: miR-375 REACTIVATION BY ANTI-CANCER DRUGS, J. Cell. Biochem, vol.116, pp.836-843, 2015. ,
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells, Cancer Cell, vol.9, pp.435-443, 2006. ,
Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity, Epigenetics, vol.12, pp.934-944, 2017. ,
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat, EMBO Mol. Med, vol.7, pp.831-847, 2015. ,
miR-605 joins p53 network to form a p53: miR-605: Mdm2 positive feedback loop in response to stress, EMBO J, vol.30, pp.524-532, 2011. ,
Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2, Life Sci, vol.190, pp.7-14, 2017. ,
Association study of miR-100, miR-124-1, miR-218-2, miR-301b, miR-605, and miR-4293 polymorphisms and the risk of breast cancer in a sample of Iranian population, Gene, vol.647, pp.73-78, 2018. ,
Emerging roles of exosomal miRNAs in breast cancer drug resistance, IUBMB Life, 2019. ,
Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies, 2019. ,
Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles, Annu. Rev. Cell Dev. Biol, vol.30, pp.255-289, 2014. ,
Exosomal miRNA Cargo as Mediator of Immune Escape Mechanisms in Neuroblastoma, Cancer Res, vol.79, pp.1293-1294, 2019. ,
Tumor exosomal microRNAs thwarting anti-tumor immune responses in nasopharyngeal carcinomas, Ann. Trans. Med, vol.5, 2017. ,
Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer, Drug Discov. Today, 2019. ,
The role of exosomes and miRNAs in drug-resistance of cancer cells, Int. J. Cancer, vol.141, pp.220-230, 2017. ,